CLINICAL TRIALS PROFILE FOR SERTRALINE HYDROCHLORIDE

All Clinical Trials for sertraline hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000321 ↗	Methamphetamine Abuse Treatment in Patients With AIDS - 1	Completed	Friends Research Institute, Inc.	Phase 4	1996-10-01	The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.
NCT00000321 ↗	Methamphetamine Abuse Treatment in Patients With AIDS - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 4	1996-10-01	The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.
NCT00000378 ↗	Antidepressant Treatment of Melancholia in Late Life	Completed	National Institute of Mental Health (NIMH)	Phase 4	1997-07-01	The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression. SSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients. Patients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication. An individual may be eligible for this study if he/she: Has unipolar major depression (with some exceptions) and is over 60 years old.
NCT00000378 ↗	Antidepressant Treatment of Melancholia in Late Life	Completed	New York State Psychiatric Institute	Phase 4	1997-07-01	The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression. SSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients. Patients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication. An individual may be eligible for this study if he/she: Has unipolar major depression (with some exceptions) and is over 60 years old.
NCT00000384 ↗	Treatment of Obsessive-Compulsive Disorder (OCD) in Children	Completed	National Institute of Mental Health (NIMH)	Phase 3	1997-05-01	The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs medication plus therapy. Some patients will receive an inactive placebo (PBO) instead of medication and/or Educational Support (ES, non-psychological treatment) instead of therapy. One in 200 children suffer from OCD, but few receive appropriate treatment. Both CBT and medication seem to be effective, but their effectiveness, alone and in combination, has not been evaluated. There are 2 phases to this trial. In Phase I the child will receive 1 of the following 6 treatments for 12 weeks: 1) SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5) SER plus ES; 6) pill PBO plus ES. If the child responds to treatment, he/she will go on to Phase II in which the treatment will be slowly reduced, then stopped (discontinued), over time to test the treatment's durability. The child will be evaluated at Weeks 1, 4, 8, 12 (Phase I treatment), and Weeks 16, 20, 24, and 28 (Phase II discontinuation) to see how effective and durable the treatment is in treating your child's OCD. A child may be eligible for this study if he/she: Has obsessive-compulsive disorder (OCD) and is 8 - 16 years old.
NCT00000384 ↗	Treatment of Obsessive-Compulsive Disorder (OCD) in Children	Completed	University of Pennsylvania	Phase 3	1997-05-01	The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs medication plus therapy. Some patients will receive an inactive placebo (PBO) instead of medication and/or Educational Support (ES, non-psychological treatment) instead of therapy. One in 200 children suffer from OCD, but few receive appropriate treatment. Both CBT and medication seem to be effective, but their effectiveness, alone and in combination, has not been evaluated. There are 2 phases to this trial. In Phase I the child will receive 1 of the following 6 treatments for 12 weeks: 1) SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5) SER plus ES; 6) pill PBO plus ES. If the child responds to treatment, he/she will go on to Phase II in which the treatment will be slowly reduced, then stopped (discontinued), over time to test the treatment's durability. The child will be evaluated at Weeks 1, 4, 8, 12 (Phase I treatment), and Weeks 16, 20, 24, and 28 (Phase II discontinuation) to see how effective and durable the treatment is in treating your child's OCD. A child may be eligible for this study if he/she: Has obsessive-compulsive disorder (OCD) and is 8 - 16 years old.

Clinical Trial Conditions for sertraline hydrochloride

Condition Name

Condition Name for sertraline hydrochloride
Intervention	Trials
Depression	77
Major Depressive Disorder	39
Healthy	17
Post-traumatic Stress Disorder	12

Condition MeSH

Condition MeSH for sertraline hydrochloride
Intervention	Trials
Depression	159
Depressive Disorder	134
Depressive Disorder, Major	74
Disease	70

Clinical Trial Locations for sertraline hydrochloride

Trials by Country

Trials by Country for sertraline hydrochloride
Location	Trials
United States	523
Canada	45
Japan	20
Brazil	17
China	15

Trials by US State

Trials by US State for sertraline hydrochloride
Location	Trials
New York	46
California	37
Pennsylvania	33
Texas	31
Massachusetts	30

Clinical Trial Progress for sertraline hydrochloride

Clinical Trial Phase

Clinical Trial Phase for sertraline hydrochloride
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	3
PHASE2	2

Clinical Trial Status

Clinical Trial Status for sertraline hydrochloride
Clinical Trial Phase	Trials
Completed	218
Terminated	36
Unknown status	26

Clinical Trial Sponsors for sertraline hydrochloride

Sponsor Name

Sponsor Name for sertraline hydrochloride
Sponsor	Trials
National Institute of Mental Health (NIMH)	53
Pfizer	29
Duke University	13

Sponsor Type

Sponsor Type for sertraline hydrochloride
Sponsor	Trials
Other	450
Industry	113
NIH	91

Sertraline Hydrochloride Clinical Trials Update, Market Analysis, and Patent-Driven Projection

Last updated: May 21, 2026

Sertraline hydrochloride is a widely marketed, off-patent antidepressant with ongoing lifecycle activity mainly focused on fixed-dose combinations, new formulations, and differentiated delivery (including liquid and pediatric-friendly options). Near-term market growth is expected to track underlying depression/anxiety treatment demand and generic supply expansion, with pricing pressure and substitution continuing across major markets.

What clinical trials are ongoing or recently completed for sertraline hydrochloride?

Clinical trial activity for sertraline is persistent but fragmented across indications (major depressive disorder, panic disorder, PTSD, OCD, social anxiety disorder), populations (pediatric, geriatric, comorbid anxiety/depression), and formulations (immediate-release tablets, liquid, oral concentrates, and formulation-biased studies). Most trials are not evidence-generating in the way that would restart exclusivity, but they often support labeling updates, switching claims (for example, pediatric administration), adherence-oriented formulations, or comparative effectiveness.

Which indications generate the most sertraline trials?

• Major depressive disorder (MDD)
• Panic disorder
• Obsessive-compulsive disorder (OCD)
• Post-traumatic stress disorder (PTSD)
• Social anxiety disorder and related anxiety phenotypes
• Adolescent depression and anxiety substudies

What trial designs show up most often?

• Randomized controlled trials comparing sertraline to other antidepressants or placebo in standard dosing ranges
• Open-label extensions assessing long-term tolerability and functional outcomes
• Bioequivalence and formulation bridging studies for generics and reformulations
• Studies focused on early symptom change and remission rates

What matters for market impact from “new trials”

For a high-generic-share molecule like sertraline, trial outcomes translate into market impact mainly when they:

• Expand labeled populations or administration conditions
• Support payer or guideline adoption in specific subgroups
• Enable differentiated product formats that reduce switching friction

How big is the sertraline hydrochloride market, and what share is captured by generics?

Sertraline is a mature, high-volume SSRI with substantial generic penetration in the US and Europe. In practice, most revenue is held by generic manufacturers selling through pharmacy channels and pharmacy benefit managers (PBMs), with branded exposure limited to the degree that substitution is constrained by formulary positioning, plan design, or patient-specific switching barriers.

Market structure

• Primary drivers: diagnosed prevalence of depression and anxiety, clinician prescribing rates, and adherence.
• Revenue is highly sensitive to:
  • generic pricing and supply dynamics
  • formulary access and PBM rebate structures
  • country-specific reimbursement and copay regimes
• Competitive landscape: dense generic lineup, with differentiation largely tied to formulation and distribution reliability rather than new pharmacology.

What segments monetize best

• Retail pharmacy (most prescriptions)
• Mail order (if PBM access is secured)
• Pediatric dosing-friendly formats where formulary restrictions or administration needs are significant

When does sertraline hydrochloride lose exclusivity, and what does that mean for pricing?

Sertraline hydrochloride’s core composition-of-matter and early method/process exclusivity have already expired in major jurisdictions, and the product is entrenched as generic.

Exclusivity reality for sertraline

• No broad, active platform exclusivity is expected to block generic competition.
• Any remaining protections are typically:
  • formulation-specific patents
  • method-of-use or specific dosing/regimen claims (if any in a given market)
  • regulatory exclusivities for specific new drug products (only if a company submits a qualifying dossier for a reformulated or newly approved product)

Market effect

• Continued price erosion and margin compression at the class level.
• Product differentiation shifts toward patient-friendly presentation and payer-preferred SKUs.

What patent estate exists for sertraline hydrochloride, and how strong are the remaining barriers?

For sertraline as a molecule, enforceable barriers are limited. The competitive set is defined less by composition-of-matter patents and more by:

• formulation patents for specific dosage forms (when present in some jurisdictions)
• trademark and branded legacy (where applicable)
• practical manufacturing/IP barriers for specific products (route/process claims are more common than “new therapeutic” claims, but are not likely to prevent generic entry at the molecule level once composition protections have expired)

Barrier types that can still matter

• Product-specific patents covering a formulation or delivery feature (if any are active for a particular branded/differentiated presentation)
• Manufacturing process patents (typically narrower)
• Orange Book listing-driven entry timing constraints (for a specific NDA or ANDA product, not the molecule broadly)

How does sertraline hydrochloride compare with other SSRIs in generic competition and clinical positioning?

Within the SSRI class, sertraline competes with citalopram, escitalopram, fluoxetine, paroxetine, and fluvoxamine, all of which face similar generic dynamics.

Key comparative factors that influence market outcomes

• Tolerability profile and switch rates
• Dosing flexibility (including ability to titrate)
• Prescriber comfort and guideline consistency
• Payer formulary placement and step-therapy rules
• Patient preference for a specific administration format

What FDA regulatory status does sertraline have, and how does that affect generic entry risk?

Sertraline is fully established in US regulation with extensive generic availability. Generic entry risk is low in the sense that the molecule is already available through many approved ANDAs, but product-level entry risk remains for specific dosage forms if a company holds active exclusivities or listed patents for a given reference product.

Regulatory pathways in a mature molecule

• Most incremental changes occur through:
  • ANDAs for generic equivalents or new dosage forms
  • supplemental approvals (labeling changes, administration instructions)
  • bioequivalence-driven approvals for new strengths or presentations

Which companies are leading the sertraline hydrochloride market, and what is the commercial outlook?

Leadership in mature generics is often determined by:

• breadth of SKU coverage (strengths, package sizes, formulations)
• ability to maintain supply continuity
• payer contracting and rebate terms
• distribution network depth

The commercial outlook for sertraline is stable-to-slightly positive in volume but constrained on price, with revenue growth driven mainly by:

• total prescriptions growth
• substitution and persistence in patients stable on sertraline
• product format advantages where they improve adherence or reduce discontinuation

Market projection for sertraline hydrochloride (volume, price, and revenue)

Projection logic for a mature generic SSRI

1. Volume: Linked to depression/anxiety prevalence, guideline-based prescribing, and continued role of SSRIs as first-line.
2. Price: Typically pressured by generic competition; revenue growth is more difficult unless:
   • supply constraints tighten pricing
   • a differentiated formulation gains formulary favor
3. Revenue: Depends on contracts, PBM positions, and scale economics.

Near-term (1–3 years)

• Stable prescription volume with incremental growth from ongoing diagnosis and treatment initiation cycles.
• Persistent unit price pressure as additional generic competition and ongoing procurement auctions continue.
• Product format competition remains key: oral liquid and pediatric-friendly versions can hold share where they improve usability.

Mid-term (3–7 years)

• Volume growth moderates as incidence and treatment rates stabilize in mature markets.
• Revenue remains sensitive to reimbursement rules and formulary changes that may shift share among SSRIs.
• Lifecycle product updates and patient-friendly formats can support share even without new exclusivity.

What generic launch scenarios exist for sertraline hydrochloride, and what could trigger supply shocks?

Generic launch scenarios

• Additional ANDA entrants at existing strengths and package sizes
• Reformulation entrants (liquid, concentrates, alternate release or stability-improved products)
• Line extensions to cover new patient needs (pediatric administration, hospital dispensing formats)

Supply-shock triggers

• Manufacturing capacity disruptions
• Raw material shortages (bulk API procurement)
• Regulatory inspections impacting one or more suppliers
• Quality events leading to temporary withdrawals

What formulation patents and product-life-cycle moves matter most for sertraline hydrochloride?

For sertraline, formulation and presentation are the main differentiators. Formulation activity commonly targets:

• pediatric administration feasibility (liquid/oral concentrate dosing accuracy)
• reduced excipient burdens or improved stability
• bioequivalence and bridging to expand available strengths
• packaging improvements that support adherence and reduce dosing errors

What is the litigation and settlement landscape for sertraline hydrochloride?

For molecules this far into generic life, litigation exists but often centers on:

• ANDA patent listings for specific reference products
• formulation or process patent disputes tied to particular NDCs

Litigation outcomes typically do not stop molecule-level generic supply long-term, but they can affect:

• timing for specific dosage forms
• price and market share for a period around settlement

Key Takeaways

• Sertraline hydrochloride is in a mature, generic-dense market; meaningful long-term exclusivity-driven impact is unlikely.
• Clinical trial activity continues, but market-relevant effects usually come through labeling refinement and formulation differentiation rather than new therapeutic monopolies.
• Market growth is expected to track prescription demand, with revenue constrained by ongoing price erosion from generic competition.
• Short-term market outcomes depend more on formulary access and supply continuity than on new intellectual property.

FAQs

1) Do new sertraline hydrochloride clinical trials change its prescribing position in depression and anxiety?
They can support labeling refinements, subgroup-specific guidance, or comparative effectiveness in specific patient types, but they do not typically reset market exclusivity for a mature generic molecule.

2) Are there still patent barriers for sertraline hydrochloride in the US?
Patent barriers are mainly product-specific (formulation, process, or method-of-use claims tied to particular approved product entries), not a broad molecule-wide restriction.

3) Does sertraline have pediatric-specific market or formulation advantages?
Pediatric dosing requirements can create demand for oral liquid or dosing-accurate presentations, which may outperform tablets in certain formularies or care settings.

4) What drives price movements for sertraline generics?
PBM contracting dynamics, procurement auctions, supply continuity, and manufacturing availability are the primary drivers.

5) How does sertraline compete with escitalopram and citalopram in formularies?
Competition is largely formulary-led. Prescriber and patient switching patterns, tolerability perception, and product availability for dosing administration influence share.

---

References (APA)

1. FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
3. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/